Bilirubin: A Promising Therapy for Parkinson's Disease

被引:17
|
作者
Jayanti, Sri [1 ,2 ,3 ]
Moretti, Rita [4 ]
Tiribelli, Claudio [1 ]
Gazzin, Silvia [1 ]
机构
[1] Fdn Italiana Fegato Onlus, Bldg Q,AREA Sci Pk,Ss14,Km 163-5, I-34149 Trieste, Italy
[2] Univ Hasanuddin, Fac Med, Makassar 90245, Indonesia
[3] Univ Trieste, Mol Biomed PhD Program, I-34127 Trieste, Italy
[4] Univ Trieste, Dept Med Surg & Hlth Sci, Neurol Clin, I-34139 Trieste, Italy
关键词
bilirubin; yellow players; disease-modifying therapy; Parkinson's disease; DOPAMINE AGONIST THERAPY; HEME OXYGENASE-1; OXIDATIVE STRESS; BILIVERDIN REDUCTASE; CLINICAL-ASPECTS; ANTIOXIDANT; NEURONS; METABOLISM; ACTIVATION; CELLS;
D O I
10.3390/ijms22126223
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Following the increase in life expectancy, the prevalence of Parkinson's disease (PD) as the most common movement disorder is expected to rise. Despite the incredibly huge efforts in research to find the definitive biomarker, to date, the diagnosis of PD still relies mainly upon clinical symptoms. A wide range of treatments is available for PD, mainly alleviating the clinical symptoms. However, none of these current therapies can stop or even slow down the disease evolution. Hence, disease-modifying treatment is still a paramount unmet medical need. On the other side, bilirubin and its enzymatic machinery and precursors have offered potential benefits by targeting multiple mechanisms in chronic diseases, including PD. Nevertheless, only limited discussions are available in the context of neurological conditions, particularly in PD. Therefore, in this review, we profoundly discuss this topic to understand bilirubin's therapeutical potential in PD.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Dopamine-iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease
    Buoso, Chiara
    Seifert, Markus
    Lang, Martin
    Griffith, Corey M.
    Andujar, Begon Talavera
    Rueda, Maria Paulina Castelo
    Fischer, Christine
    Doerrier, Carolina
    Talasz, Heribert
    Zanon, Alessandra
    Pramstaller, Peter P.
    Schymanski, Emma L.
    Pichler, Irene
    Weiss, Guenter
    NEUROBIOLOGY OF DISEASE, 2024, 196
  • [42] Th17 cells: a promising therapeutic target for Parkinson's disease?
    Prots, Iryna
    Winner, Beate
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (04) : 309 - 314
  • [43] Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson's disease
    Zhang, Yi
    Mo, Chengjun
    Ai, Penghui
    He, Xiaoqin
    Xiao, Qin
    Yang, Xiaodong
    GUT MICROBES, 2025, 17 (01)
  • [44] L-dopa therapy for Parkinson's disease: Past, present, and future
    Nagatsu, Toshiharu
    Sawada, Makoto
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S3 - S8
  • [45] 2-Methoxyestradiol and Hydrogen Peroxide as Promising Biomarkers in Parkinson’s Disease
    Paulina Bastian
    Lucyna Konieczna
    Jarosław Dulski
    Agnieszka Daca
    Dagmara Jacewicz
    Agata Płoska
    Narcyz Knap
    Jarosław Sławek
    Tomasz Bączek
    Leszek Kalinowski
    Joanna Drzeżdżon
    Anna Roszmann
    Mariusz Belka
    Magdalena Górska-Ponikowska
    Molecular Neurobiology, 2024, 61 : 148 - 166
  • [46] Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
    Stocchi, Fabrizio
    Olanow, C. Warren
    MOVEMENT DISORDERS, 2013, 28 (01) : 3 - 7
  • [47] Recent Advances in Drug Therapy for Parkinson?s Disease
    Murakami, Hidetomo
    Shiraishi, Tomotaka
    Umehara, Tadashi
    Omoto, Shusaku
    Iguchi, Yasuyuki
    INTERNAL MEDICINE, 2023, 62 (01) : 33 - 42
  • [48] New Molecular Avenues in Parkinson's Disease Therapy
    Di Napoli, Mario
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 913 - 948
  • [49] Therapeutic Effects and Mechanisms of Icaritin in Parkinson's Disease
    Zheng, Chongbo
    Wu, Lizhen
    Luo, Liang
    Cai, Jiating
    Huang, Zhihua
    Tian, Keqiang
    CURRENT PHARMACEUTICAL DESIGN, 2025,
  • [50] Homocysteine and Parkinson's disease
    Zhou, Lingyan
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (02)